WGS — GeneDx Holdings Corp.

Nasdaq · Health Care · Health Care Providers & Services · CIK 1818331 ·
Last close
$85.19
Market Cap
$2.54B
52W High
$87.17
52W Low
$46.80
ADV30
771,174
Next earnings
2026-10-27
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026 114,440,000 78,238,000 -15,243,000 -17,740,000 481,486,000 60,317,000 237,265,000
Mar 2026 102,254,000 68,211,000 -26,184,000 -63,316,000 506,301,000 93,924,000 252,177,000
Dec 2025 120,989,000 84,268,000 -14,235,000 -17,666,000 523,710,000 104,997,000 215,528,000
Sep 2025 116,743,000 84,527,000 -3,251,000 -7,635,000 493,902,000 95,968,000 201,644,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-48,712,000
Investing CF
$-38,644,000
Financing CF
$73,556,000
CapEx
$-27,086,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-2.67
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,454,551,000
Inventory
$17,820,000
Receivables
$83,610,000
ST Investments
$72,231,000
EBIT TTM
$-96,261,000
Pretax Income TTM
$-106,295,000
Interest Exp TTM
$3,359,000
Analysts
9

Yahoo Snapshot (yfinance, live)

Total Revenue
$454,425,984
EBITDA
$-33,695,000
Free Cash Flow
$-47,501,624
Enterprise Value
$2,575,436,288
Total Cash
$132,548,000
Total Debt
$167,402,000
Shares Out
29,822,541
Trailing EPS
$-3.55
Book Value
$8.19
ROE
-40.8%
ROA
-7.9%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 427,539,000 -13,077,000 -21,021,000 523,710,000 215,528,000 33,279,000
Dec 2024 305,450,000 -23,213,000 -52,286,000 419,380,000 174,133,000 -28,496,000
Dec 2023 202,566,000 -170,194,000 -175,767,000 418,756,000 190,739,000 -180,147,000
Dec 2022 234,694,000 -457,507,000 -548,980,000 490,942,000 237,237,000 -319,155,000

TTM Snapshot

Revenues TTM
$256,589,000
NetIncome TTM
$-95,448,000
OpCashFlow TTM
$0
Assets (Latest)
$419,380,000
Forward EPS
$1.17

Max Pain — expiry 2026-09-18

max pain strike: $65.00 · spot: $85.19 · call oi: 3,291 · put oi: 549
Expected Move to 2026-09-18: ±$11.62 (13.64%) — implied range $73.57$96.81 · ATM straddle on $85.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
CDNA CareDx, Inc. $2.46B $47.50
ACHC Acadia Healthcare Company, Inc. $2.67B $28.72
PRVA Privia Health Group, Inc. $2.68B $21.02
ADUS Addus HomeCare Corp $2.26B $120.82
BKD Brookdale Senior Living Inc. $2.89B $12.12

News headlines (Yahoo Finance, 1h cache)

GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’s
2026-08-24 12:30 · Yahoo
Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates?
2026-08-19 16:20 · Yahoo
GeneDx (WGS) Q2 2026 Earnings Call Transcript
2026-08-11 01:46 · Yahoo
GeneDx Holdings Corp (WGS) (Q2 2026) Earnings Call Highlights: Record Volume and Early ...
2026-08-04 05:07 · Yahoo
GeneDx Q2 Earnings Call Highlights
2026-08-03 23:03 · Yahoo
GeneDx Holdings Corp. (WGS) Slid as Revenue Fell Short of Expectations
2026-07-21 14:04 · Yahoo
GeneDx to Report Second Quarter 2026 Financial Results on Monday, August 3, 2026
2026-07-16 20:05 · Yahoo
GeneDx to Participate in Upcoming Investor Conferences
2026-08-06 20:05 · Yahoo
What a $227,000 GeneDx Insider Sale Means as Revenue Climbs 17%
2026-06-23 22:08 · Yahoo
GeneDx Names Mark Gardner President to Lead Its Next Phase of Scale and Growth
2026-06-16 12:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.